Trials
9 active
10 in total
Targets
—
None known yet
What this is
- How it works
- A cancer drug that hits two targets at once: it releases a brake on the immune system (PD-1 or PD-L1) and starves the tumour of blood vessels (VEGF).PD-1/VEGF bispecific antibody
- How it’s given
- “The dose for Phase III will be determined based on Phase II results.”In the company’s words, NCT07935369 on ClinicalTrials.gov
- Tested for
- Non-Small Cell Lung Cancer (2 trials), Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Colorectal (Colon or Rectal) Cancer, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Breast Cancer, Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology, Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy, Solid Tumor
- Main trialPhase 3
- “This study aims to evaluate the efficacy and safety of RC148 combined with platinum-based chemotherapy versus Tislelizumab combined with platinum-based chemotherapy in participants with locally advanced or metastatic Squamous NSCLC who have not received first-line treatment. Participants will: Take RC148 or Tislelizumab combined with platinum-based chemotherapy until the end of the research.”In the company’s words, NCT07416474 on ClinicalTrials.gov
Coming up6
- 12 May 2027Phase 2/3 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- Jul 2028Phase 2 trial completes · ClinicalTrials.gov
- 30 Apr 2030Phase 2/3 trial completes · ClinicalTrials.gov
- Apr 2031Phase 3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 13 NovNew trial: none to Phase 2/3 · ClinicalTrials.gov NCT07935369
- 12 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07829549
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 Dec 2027 | RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) | |
| Phase 3Recruiting | Apr 2031 | Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations | |
| Phase 2/3Recruiting | 12 May 2027 | A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer | |
| Phase 2/3Not yet recruiting | 30 Apr 2030 | RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma | |
| Phase 2Recruiting | 1 Oct 2026 | Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer | |
| Phase 2Not yet recruiting | Dec 2027 | Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer | |
| Phase 2Not yet recruiting | Jul 2028 | Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer | |
| Phase 1/2Recruiting | 31 Dec 2025 | A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors | |
| Phase 1Active, not recruiting | 31 Aug 2026 | A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC | |
| Phase 1/2Unknown | 28 Feb 2026 | A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 · EU trials register (CTIS) updated 16 Nov 2026 · openFDA updated 13 Nov 2026